PharmaShots | Incisive News in 3 Shots

Subscribe Now

Chronic HCV Patients

AbbVie's Maviret (glecaprevir/pibrentasvir) Receives EC's Marketing Authorization as Eight-Week Regimen for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis

AbbVie's Maviret (glecaprevir/pibrentasvir) Receives EC's Marketing Authorization as Eight-Week Regimen for Treatment-Naïve Chroni...

March 9, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us